AdvanCell
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
$315MSeries D
Role not disclosedEL
Eli Lilly and Company
Activity from announced rounds
Activity in this selectionAustralia
Eli Lilly and Company is a medicines developer that also finances external innovation and provides laboratory and development resources to early biotechnology companies.
Its Catalyze360 platform combines several ways to work with a startup. Lilly Ventures provides investment; Lilly Gateway Labs provides laboratory facilities and scientific engagement; Lilly ExploR&D provides research and development capabilities.
The platform engages biotechs at the earliest stages across therapeutic areas. Its investment remit extends into new scientific platforms and health technology, giving founders routes to strategic capital and development infrastructure through different parts of Lilly’s external innovation organisation.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $315M 1 disclosed · full round size, not this investor’s share